dimecres, 10 d’abril del 2019

FTC grants final approval for Fresenius’s $2B buyout of NxStage

Fresenius Medical Care acquires NxStage Medical

The U.S. Federal Trade Commission said yesterday that it granted a final order of approval to Fresenius Medical Care (NYSE:FMS; ETR:FRE) for its $2 billion acquisition of NxStage Medical.

The approval came with a caveat that the companies divest their assets and rights to research, develop, manufacture, market and sell NxStage’s bloodline tubing sets intended for use during hemodialysis treatment.

To mollify the anti-trust regulators, NxStage last July agreed to deal its Medisystems bloodlines business to B. Braun.

The final order was approved in a three-to-two vote, according to an FTC posting.

The $30-per-share deal for the Lawrence, Mass.-based home hemodialysis pioneer, first announced in August 2017, was initially slated to close by the end of that year. But it was delayed several times by the government shutdown this year and by the FTC.



from MassDevice http://bit.ly/2P2jXFr

Cap comentari:

Publica un comentari a l'entrada